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Sphingosine-1-phosphate receptor 1 (S1P
 
1
 
) was recently shown to be required for 
lymphocyte egress from lymphoid organs. Here we have examined the relationship between 
S1P
 
1 
 
abundance on the cell and egress efficiency. Using an integrin neutralization approach 
to separate the processes of entry and exit, we show that pertussis toxin treatment reduces 
lymphocyte egress from lymph nodes. Retrovirally mediated S1P
 
1 
 
overexpression is sufficient 
to reduce B cell accumulation in the splenic white pulp and to promote egress of activated T 
cells from lymph nodes, whereas S1P
 
1
 
 
 
/
 
  
 
cells have reduced lymph node exit efficiency. 
Furthermore, lymphocyte S1P
 
1 
 
is down-regulated in the blood, up-regulated in lymphoid 
organs, and down-regulated again in the lymph. We propose that cyclical ligand-induced 
modulation of S1P
 
1 
 
on circulating lymphocytes contributes to establishing their lymphoid 
organ transit time.
 
After entering a secondary lymphoid organ
from the blood, naive lymphocytes travel to
separate subcompartments where they survey
for antigen. In the absence of antigen encoun-
ter, the cells leave the organ via the efferent
lymphatics or in the case of the spleen, via the
red pulp. Timely egress ensures that the cells
travel rapidly to further lymphoid organs to
continue their antigen-surveillance process.
The molecular mechanisms of lymphocyte entry
into secondary lymphoid organs have been
well characterized over the past several decades;
however, the molecules involved in lympho-
cyte exit are just starting to be realized.
Integrins are essential for lymphocyte entry
into peripheral lymphoid organs (1–3). The
integrin 
 
 
 
L
 
 
 
2 (LFA-1) plays a major role and
 
 
 
2-deficient lymphocytes exhibit 
 
 
 
50% re-
duced homing to peripheral lymph nodes. 
 
 
 
4
integrins, 
 
 
 
4
 
 
 
1 and 
 
 
 
4
 
 
 
7, account for the re-
maining integrin requirement during entry,
and when both 
 
 
 
L
 
 
 
2 and 
 
 
 
4 integrins are
blocked with neutralizing antibodies, lympho-
cyte entry into lymph nodes is inhibited by
 
 
 
98% (1). Integrin function during entry into
lymphoid organs is controlled at least in part
through the actions of chemokine receptors
and associated G
 
 
 
i signals (3, 4). Despite the
well-established requirement for integrins dur-
ing entry from blood into lymphoid organs, it
is unclear whether integrins are involved dur-
ing egress.
Recently, lymphocyte egress from second-
ary lymphoid organs and thymus was found
to depend on expression of sphingosine-1-
phosphate receptor 1 (S1P
 
1
 
) within the lym-
phocyte (5, 6). The S1P
 
1 
 
ligand, S1P, is present
at high concentrations (100–300 nM) within
blood and body fluids (7, 8). S1P
 
1 
 
couples to
G
 
 
 
i and stimulates a variety of events within
cells in response to S1P, including chemotaxis
(9). The G
 
 
 
i requirement for T cell egress
from the thymus has been suggested to reflect
the role of G
 
 
 
i downstream of S1P
 
1 
 
(6, 10).
The requirement of G
 
 
 
i for lymphocyte entry
into lymph nodes and splenic white pulp is
well established, but whether G
 
 
 
i signaling is
required for egress of lymphocytes from sec-
ondary lymphoid organs has been unclear.
The immunosuppressant drug, FTY720,
blocks egress of lymphocytes from lymph nodes,
Peyer’s patches, and thymus (11–13). In vivo,
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FTY720 is phosphorylated and in vitro analysis established
that FTY720-phosphate is an agonist for S1P
 
1 
 
and three of
the four other S1P receptors (14, 15). However, after expo-
sure to FTY720 for several hours, transfected cell lines ex-
hibit prolonged down-regulation of S1P
 
1
 
, and it has been
suggested that the egress-blocking activity of FTY720 can be
explained by its S1P
 
1 
 
down-modulating activity on lym-
phocytes (6, 16). Although the inhibitory effects of FTY720
on egress from lymph nodes and Peyer’s patches have been
firmly established, its effects on recirculating lymphocytes in
the spleen have been less clear as spleen lymphocyte num-
bers decrease after treatment (11, 17), and the drug causes
a shift in viral-specific CTLs from spleen to lymph nodes
(18).
In this study we have examined the relationship between
S1P
 
1 
 
abundance in the cell and transit through lymphoid
tissues. We first established that 
 
 
 
4 and 
 
 
 
2 integrins are not
required for lymphocyte exit and we then used integrin
neutralization as an approach to block entry and study re-
quirements for exit. We find that pertussis toxin (PTX)
treatment causes a reduction in lymphocyte exit, establishing
that G
 
 
 
i signaling has a positive role in egress. S1P
 
1 
 
overex-
pression in activated B cells reduces their accumulation in
the splenic white pulp and restores the ability of activated T
cells to egress from lymph nodes. Reciprocally, S1P
 
1
 
    
 
cells
are shown to have reduced egress efficiency. Finally, we es-
tablish that S1P
 
1 
 
receptor levels are down-regulated on lym-
phocytes during transit through the blood and lymph and
up-regulated within the lymphoid organs. We propose that
cyclical modulation of S1P
 
1 
 
on circulating lymphocytes in-
fluences their transit time through lymphoid organs.
 
RESULTS
 
 
 
4 and 
 
 
 
2 integrins are not essential for egress from 
secondary lymphoid tissues
 
To test whether integrins were required during lymphocyte
egress from lymph nodes, we examined the effect of treating
mice with a combination of 
 
 
 
4 and 
 
 
 
L neutralizing antibod-
ies. Within 20 min of treatment, surface integrins on circu-
lating lymphocytes were saturated with the antibodies and
entry into lymph nodes was blocked (not depicted). When
mice were treated for 26 h there was an 80–90% decrease in
lymph node cell number compared with control treated
mice (Fig. 1 A). By contrast, lymphocyte numbers in blood
increased, consistent with continued release of cells from
lymphoid organs in the absence of further entry (not de-
picted). Analysis of cells within lymph nodes revealed that
integrin saturation with neutralizing antibodies was not
achieved for 8–10 h, in agreement with studies showing that
antibodies are poorly able to penetrate lymph nodes (19).
However, lymph node cell numbers continued to decrease
between 14 and 26 h of antibody treatment, indicating that
exit was still able to occur after all lymphocyte 
 
 
 
4 and 
 
 
 
L in-
tegrins had been neutralized (Fig. 1 A).
As a further approach to specifically test the 
 
 
 
2 integrin
requirement during exit, 
 
 
 
2
 
    
 
splenocytes were adoptively
Figure 1. Lack of integrin requirement but role for G i during lym-
phocyte egress. (A) Effect of treatment with a combination of  4 and  L 
neutralizing antibodies for the indicated times on B220  B cell numbers, and 
CD4 and CD8 T cell numbers in mesenteric lymph nodes. Each bar represents 
the mean (  SD) for at least five mice per group. (B) Egress of  2    cells 
from lymph nodes. CFSE-labeled  2    splenocytes were transferred into 
wild-type (WT) mice, and after 32 h, the mice were treated with saline or 
FTY720 for 6 h and then either analyzed (0 h) or treated with  4 antibodies 
to block further entry of transferred  2    cells and analyzed after 15 h. 
Panels show numbers of transferred  2    cells in mesenteric lymph nodes. 
Bars show mean (  SD) numbers of transferred B220, CD4, and CD8 cells 
from mesenteric lymph nodes of the indicated mice. Data are pooled from 
two experiments with at least four animals in each group. (C) Determination 
of the time needed for PTX-mediated inhibition of chemotaxis. Wild-type 
splenocytes were treated with PTX or saline (ctrl) for 2 h or treated with PTX 
for 10 min, washed, and then further incubated for the indicated times. All 
cells were then subjected to chemotaxis assays with 0.3  g/ml CXCL12 or no 
chemokine (nil). The data depict the percent of input CD4 T cells that mi-
grated and are representative of two experiments. (D) Persistence of PTX 
inhibitory effects in vivo. CD45.1  splenocytes were treated for 10 min with 
2 ng/ml PTX or saline, washed twice, and then adoptively transferred into 
CD45.2  wild-type mice. 4 or 26 h later, recipient lymph node cells were 
harvested and subjected to chemotaxis assays. Bars show means of dupli-
cates for CD45.1  CD4 T cell chemotaxis to 1  g/ml CCL21 (SLC) and are 
representative of two experiments. (E) PTX sensitivity of lymphocyte exit 
from lymph nodes. CFSE-labeled  2    splenocytes were treated with oligo-
mer B (Oligo. B) or PTX for 10 min, washed twice, and then adoptively trans-
ferred into wild-type mice. After 3 h, mice were analyzed (0 h) or treated 
with  4 antibodies for 23 h, and then analyzed for numbers of transferred 
cells as indicated. Mean (  SD) values are shown for the indicated number 
of animals. Two-tailed student’s t test was performed between the indicated 
(underlined) groups. The percent of transferred cells remaining (% Remain-
ing) within each type of lymph node was calculated by dividing the number 
of cells recovered at 23 h by the number recovered at 0 h. 
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transferred into wild-type recipient mice, allowed to equili-
brate for 32 h, and then the mice were treated with neutral-
izing anti-
 
 
 
4 antibodies (Fig. 1 B). 
 
 
 
4 neutralization on its
own has only a weak inhibitory effect on lymph node entry
of wild-type cells but causes an almost complete block in en-
try of 
 
 
 
2
 
    
 
cells (1). A significant (
 
 
 
95%) decrease occurred
in the number of transferred 
 
 
 
2
 
    
 
cells in lymph nodes 15 h
after entry was blocked, whereas the number of endogenous
cells remained similar over the course of the treatment (Fig.
1 B and not depicted).
To test whether FTY720-mediated sequestration of lym-
phocytes within lymph nodes was integrin dependent, recip-
ients of 
 
 
 
2
 
    
 
cells were treated with FTY720 6 h before
treatment with 
 
 
 
4 neutralizing antibodies. 15 h later, the
number of 
 
 
 
2
 
    
 
cells in the FTY720-treated group had not
changed in contrast to the 20-fold decrease in 
 
 
 
2
 
    
 
cell
numbers in mice not treated with the drug (Fig. 1 B). These
observations establish that 
 
 
 
2 and 
 
 
 
4 integrins are not re-
quired for T and B lymphocyte egress from lymph nodes or
for FTY720-induced sequestration of cells.
 
G
 
 
 
i inhibition reduces lymphocyte exit from lymph nodes
 
To examine whether G
 
 
 
i signaling contributes to lympho-
cyte exit, we tested the effect of treatment with PTX, an en-
zyme that ADP-ribosylates and inactivates G
 
 
 
i (20). Because
G
 
 
 
i is essential for lymphocyte entry into lymphoid organs,
it was not possible to use the conventional method of G
 
 
 
i
inactivation by 100–200 ng/ml PTX treatment for 1–2 h
before cell transfer. In vivo PTX treatment was also consid-
ered a problematic approach as G
 
 
 
i function is critical in
many cell types in addition to lymphocytes; for example,
functioning to help maintain vascular integrity (9). Instead,
we developed an approach where cells are pulsed with PTX
for 10 min to load them with the toxin and then transferred
to wild-type recipients. Immediately after such pulse load-
ing, we found that minimal inhibition of G
 
 
 
i function had
occurred, but partial inhibition was evident after 60 min and
almost complete inhibition after 90 min as assessed by che-
motactic responsiveness to CXCL12 (Fig. 1 C). During ini-
tial tests to track PTX-pulsed cells in vivo after transfer, we
observed lymphocytosis of endogenous cells, indicating that
PTX was leaking from the treated cells and having trans ef-
fects (not depicted). Therefore, we performed titration ex-
periments and found that a 10-min treatment with 2 ng/ml
PTX was adequate to cause a substantial (
 
 
 
75%) inhibition
of CCL21 chemokine responsiveness after 4 h (Fig. 1 D),
while having minimal effects on endogenous lymphocytes
(not depicted). The inhibitory effect in the transferred cells
was still evident after 26 h (Fig. 1 D). The same experiment
performed at the high PTX dose resulted in 
 
 
 
95% inhibi-
tion in the CCL21 response (not depicted).
To determine the contribution of G
 
 
 
i signaling to lym-
phocyte exit, 
 
 
 
2
 
    
 
cells were pulsed with 2 ng/ml PTX or,
as a control, the non-ADP ribosylating oligomer B subunit
of PTX, washed and transferred to wild-type recipient mice.
After 3 h, these animals were treated with anti-
 
 
 
4 antibodies
to block any further entry of 
 
 
 
2
 
    
 
cells (Fig. 1 E). Enumer-
ation 23 h later revealed that although the number of CD4 T
cells decreased between 0 and 23 h, 14% of the transferred
PTX-treated cells remained in the mesenteric lymph node,
whereas only 2% of the oligomer B control-treated cells re-
mained (Fig. 1 E). Similar findings were made for peripheral
lymph nodes (Fig. 1 E) as well as for CD8 T cells and B cells
(not depicted). Experiments were also performed with cells
pulsed with the high dose of PTX (or oligomer B) and
yielded  22% PTX-treated CD4 T cells remaining com-
pared with  6% oligomer B–treated cells in peripheral
lymph nodes (not depicted). These results indicate that G i
signaling contributes to the efficiency of lymphocyte exit
from lymph nodes.
S1P1 overexpression reduces B cell localization 
in the splenic white pulp
To better understand the role of S1P1 during lymphocyte re-
circulation, we tested whether S1P1 overexpression was suffi-
cient to promote lymphocyte egress from secondary lym-
phoid tissues. Activated B cells were transduced with a
retrovirus containing a Flag-tagged S1P1 insert and a human
CD4 (hCD4) reporter, or with a control retrovirus lacking
the S1P1 insert, and transferred into wild-type recipient mice.
Transferred B cells were recovered from the blood and spleen
1 d later, but insufficient numbers homed into lymph nodes
for analysis, possibly due to their activated state. S1P1-trans-
duced cells isolated ex vivo from the spleen responded
robustly to S1P in chemotaxis assays compared with vec-
tor-transduced cells (Fig. 2 A). To examine whether S1P1
overexpression led to altered cell trafficking within the spleen,
immunohistochemical analysis was performed on recipient
spleens isolated 15 h after cell transfer. In contrast to the pre-
dominantly follicular distribution of vector control cells, most
of the S1P1-overexpressing cells were localized in the red
pulp (Fig. 2, B and D). To determine whether this effect on
cell distribution was reversible, recipient mice were treated
with FTY720. Although the treatment did not appear to alter
the splenic compartmentalization of vector-transduced cells
(not depicted), it was sufficient to cause relocalization of
S1P1-overexpressing cells into the white pulp (Fig. 2, C and
D). FTY720 treatment led to reduced S1P chemotactic re-
sponsiveness of the S1P1-overexpressing cells (Fig. 2 E). Fur-
thermore, Flag-S1P1 surface levels were decreased (Fig. 2 F),
extending previous in vitro findings that FTY720 exposure
causes down-modulation of S1P1 in cell lines (6, 16). These
results establish that elevated S1P1 expression reduces accu-
mulation of B cells in the splenic white pulp, possibly by fa-
voring white pulp exit over entry, and that in vivo treatment
with FTY720 causes S1P1 down-modulation. By contrast
with these findings for B cells, S1P1-transduced activated T
cells were not altered in their homing to the splenic T zone
(not depicted). The basis for this difference between trans-
duced B and T cells is not clear, although it is notable that B
and T cells have differing requirements for entry into the
splenic white pulp (2, 21). However, the activated T cellsS1P1 AND LYMPHOCYTE RECIRCULATION | Lo et al. 294
were able to enter lymph nodes in greater numbers than the
B cells, permitting experiments to test effects of S1P1 overex-
pression on lymph node egress.
Exit of activated T cells from lymph nodes is restored by 
S1P1 overexpression
After activation, T cells down-regulate S1P1 mRNA and are
retained in lymph nodes for a period of 2–3 d (6, 22). To de-
termine whether S1P1 down-regulation is sufficient to explain
the retention of activated T cells, we tested the effect of re-
storing S1P1 expression by retroviral gene transduction (Fig. 3
A). Analysis of the input cells before adoptive transfer showed
that S1P1 transduction was more efficient than transduction
with the control virus and hCD4 expression was higher (Fig.
3 A). The basis for this difference was not clear but it was sta-
bly maintained after the cells were transferred to recipient
mice. S1P1 transcripts were 10–20-fold more abundant in
S1P1-transduced cells than in the vector control cells and
about threefold more abundant than in naive T cells (Fig. 3
A). CD45.1  carboxyfluorescein succinimidyl ester (CFSE) 
vector and CD45.1  CFSE  Flag-S1P1-transduced T cells
were cotransferred into CD45.2  wild-type recipient mice,
and after a 1-d equilibration period (time   0 h), further
lymph node entry was blocked by treating with integrin-neu-
tralizing antibodies. After 15 h, the frequency of hCD4  cells
amongst the transferred vector-transduced cells remained sim-
ilar to the 0-h time point, indicating that transduction with
the empty vector did not alter the trafficking of the cells (Fig.
3 B). As expected, few of the activated vector-transduced cells
exited the lymph node during the 15 h, decreasing less than
Figure 2. S1P1 overexpression reduces B cell localization in the 
splenic white pulp. (A) S1P chemotactic responsiveness of Flag-S1P1 and 
vector-transduced B cells isolated from recipient spleens 15 h after transfer, 
shown as percent of input hCD4  cells of the indicated type that migrated. 
(B) Immunohistochemical analysis of spleen sections from wild-type mice 
that had received either vector or Flag-S1P1–transduced cells 15 h earlier. 
Transferred transduced B cells were detected by hCD4 staining (brown) 
and endogenous B cells detected by B220 staining (blue). Objective magni-
fication of 5. (C–E) Effects of FTY720 treatment on S1P1-overexpressing 
B cell distribution. Flag-S1P1–and vector-transduced B cells were trans-
ferred into wild-type mice for 15 h and the mice were then treated with 
saline or FTY720 for a further 6 h. (C) Immunohistochemical analysis of 
spleen sections stained to detect transferred B cells (hCD4, blue) and the 
marginal sinus-lining cells (MAdCAM-1, brown). The latter marker delineates 
the boundary between the red pulp (RP) and white pulp (WP). Objective mag-
nification of 10. (D) Quantitation of the number of hCD4  cells per white 
pulp cord in the groups shown in B and C. The number of transferred cells 
in at least four white pulp cords of similar size were enumerated in each 
type of recipient. (E) S1P chemotactic responsiveness of Flag-S1P1–transduced 
cells from transfer recipients treated with saline or FTY720 for 6 h as indi-
cated. (F) Flow cytometric analysis for Flag epitope staining on hCD4  
Flag-S1P1– or vector-transduced cells from spleens of transfer recipients 
treated for 6 h with saline or FTY720 as indicated. The data in A–E are rep-
resentative of at least three experiments.JEM VOL. 201, January 17, 2005 295
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twofold in number, compared with a sixfold decrease in the
number of endogenous naive T cells over this period (Fig. 3,
B and C). By contrast, the hCD4  S1P1-expressing cells ex-
hibited a significant decrease in frequency amongst the trans-
ferred cells 15 h after entry was blocked (Fig. 3 B), and their
egress efficiency was increased to a level exceeding that of the
endogenous naive cells (Fig. 3 C). To further test whether the
greater reduction in cell number of the S1P1-overexpressing
group was due to increased egress, some of the recipient mice
were treated with FTY720 before integrin neutralization. In
these animals, S1P1 overexpression had no effect on cell fre-
quency or number over time (Fig. 3, B and C). These results
demonstrate that S1P1 overexpression is sufficient to promote
exit of activated T lymphocytes from lymph nodes.
S1P1 heterozygous cells are impaired in their ability to exit 
lymph nodes
As another approach to test the sensitivity of lymphocyte egress
to S1P1 levels, we asked whether egress efficiency was altered
in S1P1 heterozygous cells. By flow cytometric analysis, surface
S1P1 levels on S1P1
    cells were reduced compared with
wild-type cells (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20041509/DC1). S1P1
 /  and S1P1
    cells
were cotransferred into wild-type recipients and allowed 32 h
for equilibration in the animal. The mice were then treated
with neutralizing  4 and  L antibodies to block further cell
entry into lymph nodes, or with saline as a control, and trans-
ferred cell numbers were enumerated in lymph nodes either at
this time (time   0 h) or 15 h later (time   15 h). As in the
experiments shown in Fig. 3 C, total lymph node cell numbers
decreased approximately sixfold after the antibody treatment
(not depicted). Flow cytometric analysis of peripheral lymph
nodes showed that although the frequency of transferred wild-
type (CFSElo) cells did not change substantially over time, indi-
cating that they were leaving the tissue at the same rate as the
endogenous cells, the frequency of S1P1
    (CFSEhi) cells in-
creased, indicating less efficient exit (Fig. 4, A and B). Similar
findings were made for mesenteric lymph nodes (Fig. 4 B). We
also observed that the frequency of mature L-selectinhi CD4
and CD8 single positive cells was increased in the thymus of
Figure 3. Exit of activated T cells from lymph nodes is restored by 
S1P1 overexpression. (A) Upper diagram shows the experimental strategy. 
Lower left panels, hCD4 expression on activated CD45.1  T cells that had 
been transduced with vector or S1P1-containing retrovirus, immediately 
before transfer (Input) to recipient mice. Lower right panel, quantitative 
PCR analysis of total S1P1 transcript levels in vector or S1P1-transduced 
hCD4 -purified T cells after 48 h in vitro culture, or in naive T cells shown 
relative to HPRT. (B) Vector- and S1P1-transduced cells were cotransferred 
into wild-type recipients and after 26 h the mice were treated with saline 
or FTY720 for 6 h followed by anti-integrin antibodies. Transferred cells 
were identified by staining for CD45.1 and CD4 plus CD8, as indicated in 
the upper panels. The frequencies of transferred vector- (CFSE ) or S1P1- 
(CFSE ) transduced hCD4  T cells in mesenteric lymph nodes as a propor-
tion of the transferred cells were determined at time 0 and 15 h after integrin 
neutralization. Frequencies are the mean (  SD) values of at least five 
mice per group and are pooled from four experiments. The frequency of 
hCD4  cells in the S1P1-transduced population at 15 h in  4 and  L 
antibody-treated recipients was significantly reduced compared with the 
frequency present at 0 h (P   0.005; Student’s t test). (C) Number of 
transferred vector- and S1P1-transduced cells and endogenous cells in the 
mesenteric lymph nodes at time 0 (white bars) and 15 h (gray bars) after 
anti-integrin antibody treatment with or without FTY720 treatment as in-
dicated. Bars represent the mean (  SD) value for three mice per group 
except for the integrin-neutralization groups where there were two mice 
per group (here the error bars represent the range). Data are representa-
tive of two experiments.S1P1 AND LYMPHOCYTE RECIRCULATION | Lo et al. 296
S1P1
    mice compared with littermate controls, suggesting
that thymic egress was reduced (not depicted). These results
indicate that a partial reduction in S1P1 abundance in the cell
impairs egress efficiency from lymphoid organs.
S1P1 surface levels modulate cyclically during 
lymphocyte recirculation
Because plasma contains high (100–300 nM) amounts of
S1P, we tested the possibility that S1P1 is down-regulated on
cells circulating in the blood compared with cells within
lymphoid organs. We first examined surface expression of
Flag-S1P1 on transferred retrovirally transduced cells. Within
15 min of transfer, Flag-S1P1 levels were reduced on cells
within the blood, and after 45 min, the cells had lost most of
their surface staining (Fig. 5 A). To test whether surface ex-
pression was restored after cells migrated into lymphoid or-
gans, transfer recipients were analyzed after 32 h, a time
point when retrovirally transduced cells are present in spleen,
lymph nodes, and lymph as well as blood. Flag-S1P1–trans-
duced T cells in the blood exhibited minimal Flag staining
compared with the vector control, whereas cells isolated
from spleen and lymph nodes showed up-regulation com-
pared with cells in the blood (Fig. 5 B). Flag-S1P1 levels
were down-regulated again on cells present in the lymph
(Fig. 5 B).
Using a newly generated anti–mouse S1P1 antiserum, we
were able to confirm these findings for endogenous S1P1 on
naive CD4 L-selectinhi T cells, showing that S1P1 was ex-
pressed on the surface of cells in spleen and lymph nodes but
was down-regulated on cells from blood or lymph (Fig. 5
C). The specificity of the antiserum for S1P1 was confirmed
by analysis of mature single positive thymocytes from S1P1-
deficient fetal liver chimeras (Fig. S1). Consistent with the
above findings, treatment of mice with FTY720 caused
down-modulation of S1P1 on lymph node cells (Fig. 5 C)
and mature thymocytes (Fig. S1). Furthermore, if lymph
node cells were incubated in vitro with mouse plasma, they
rapidly down-regulated S1P1 (Fig. 5 D). Finally, when S1P1
abundance was measured on adoptively transferred spleno-
cytes after entry into lymph nodes, S1P1 was partially up-
regulated by 1.5 h and fully up-regulated by 4 h compared
with cells that had been transferred 24 h previously (Fig.
5 E). Taken together, these observations demonstrate that
S1P1 modulates cyclically in cell surface levels as lymphocytes
recirculate from the blood into secondary lymphoid organs
and then into the blood or lymph.
DISCUSSION
The above findings established that S1P1 overexpression was
sufficient to reduce B cell accumulation in the splenic white
pulp and to overcome retention of activated T cells in lymph
nodes, whereas S1P1 heterozygous deficiency in naive lym-
phocytes was associated with reduced lymph node egress.
Furthermore, wild-type lymphocytes were found to down-
modulate S1P1 during transit through lymph and blood and a
transferred cohort of cells required more than an hour to
fully up-regulate the receptor upon entering a lymphoid tis-
sue. These findings suggest that there is normally a delay be-
tween when a cell enters a lymphoid tissue and when it re-
gains full egress competence (Fig. 6), a delay that might help
ensure the cell dwells in the tissue and does not immediately
undergo the exit program. To our knowledge, S1P1 is the
first example of a receptor that is down-modulated on cells
circulating in the blood or lymph and then reexpressed on
cells that migrate into tissues.
Figure 4. Reduced exit efficiency of S1P1 heterozygous cells. 
(A) S1P1 wild-type and heterozygote splenocytes were labeled with low or 
high amounts of CFSE, respectively, cotransferred into wild-type mice, and 
equilibrated for 32 h, followed by 0 or 15 h of  4 plus  L antibody or saline 
treatment. Gates show the frequencies of cotransferred S1P1 wild-type 
(CFSElo) and heterozygote (CFSEhi) B220  cells (left) and CD4  and CD8  cells 
(right) recovered from a pool of brachial and inguinal (peripheral) lymph 
nodes as a percent of total lymph node cells. The data shown are from one 
experiment that is representative of three experiments with three mice per 
group. (B) Ratio of S1P1 heterozygote and wild-type cotransferred cells 
within the mesenteric and peripheral lymph nodes (LN) at 0 (white bars) or 
15 h of saline treatment (gray bars) or 15 h of  4 plus  L antibody treat-
ment (black bars). Bars show the mean (  SD) for three mice per group in 
one experiment. Representative of three similar experiments.JEM VOL. 201, January 17, 2005 297
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Lymphocyte exit from lymph nodes and Peyer’s patches
is thought to involve reverse transmigration across lymphatic
endothelial cells (23–25). The lack of an essential role for  4
or  2 integrins during lymphocyte egress from lymph nodes
is consistent with in vitro studies showing that reverse trans-
migration does not require  4 or  2 integrins (26). A study
tracking lymphocyte migration through rat Peyer’s patches
also concluded that  4 integrins were not required for egress
(23) and in a recent report, egress of activated T cells from
lymph nodes was not blocked by integrin neutralizing anti-
bodies (27). Moreover, we failed to observe release of  2   
cells from lymph nodes of FTY720-treated mice after 15 h
of  4 antibody treatment, providing evidence that integrin-
mediated adhesion is not involved in mediating FTY720-
induced lymphocyte sequestration. The finding that lymph
node egress is partially PTX sensitive is consistent with the
S1P1 requirement during this step as G i is the only defined
G  signaling partner for this receptor (9). Lymphocyte egress
from the thymus is also sensitive to the enzymatic subunit of
PTX and depends on G i2 and S1P1 (5, 6, 10). However, it
is notable that we did not observe a complete block in
lymph node egress even after PTX exposures that were suffi-
cient to inhibit lymph node entry. One explanation for these
observations may be that the PTX treatment failed to inacti-
vate all of the G i molecules and a smaller fraction of total
cellular G i may be needed during exit than during entry.
Alternatively, S1P1 may signal in part via PTX insensitive G
proteins, a possibility supported by evidence that S1P1 can
activate Rho, a small G protein usually thought to be down-
stream of G 12/13 rather than G i (9). Our experiments
also do not exclude the possibility that the reduced egress of
PTX-treated cells is due to a reduced ability to migrate to
exit sites, perhaps in response to chemokines, rather than be-
ing due to an effect on exit itself. In a recent report where
mice were treated in vivo with PTX, it was concluded that
lymphocyte egress was not affected (27). However, the in-
terpretation of these experiments is complicated by the evi-
dence that G i-coupled receptors are important for vascular
integrity (9, 28) and might be required in a variety of cell
types for maintaining lymphoid tissue function.
Figure 5. S1P1 surface levels modulate cyclically during recircula-
tion. (A) Flow cytometric analysis of cell surface Flag epitope on hCD4  
Flag-S1P1–transduced B cells before transfer (input, blue) or in the blood 
of recipient mice 15 (15 min, red) or 45 min (45 min, green) after transfer, 
compared with cells transduced with empty vector (vector, black). (B) Flow 
cytometric analysis of Flag levels on Flag-S1P1–transduced T cells during 
lymphocyte recirculation. Flag staining of Flag-S1P1– (blue) transduced 
cells (hCD4 ) in the blood, spleen, peripheral lymph nodes, and lymph 
compared with staining of vector transduced cells (left, black) or to Flag-
S1P1–transduced cells in the blood (red). Individual histograms are from 
different experiments and are each representative of four experiments. 
(C) Flow cytometric analysis of endogenous S1P1 levels on CD4 L-selectinhi 
T cells in the indicated tissues of untreated or FTY720-treated mice. Data 
are representative of more than six untreated mice for blood, spleen, and 
lymph node, three treated mice for spleen and lymph node, and for four 
pools of lymph representing two or three mice. (D) Flow cytometric analy-
sis of endogenous S1P1 levels on lymph node CD4  L-selectinhi T cells after 
45 min of incubation with medium (untreated) or a 1/20 dilution of mouse 
plasma (plasma). Data are representative of three experiments. (E) Flow 
cytometric analysis of S1P1 levels on transferred CD4  L-selectinhi T cells 
isolated from recipient lymph nodes at the indicated times after transfer. 
Data are representative of four similar experiments (five mice total). In 
C–E, control refers to cells stained with an irrelevant rabbit antiserum.S1P1 AND LYMPHOCYTE RECIRCULATION | Lo et al. 298
Most of the lymphocytes in the spleen are localized
within the white pulp but as many as one third of the cells
are in the nonlymphoid red pulp, a region through which
blood filters from open-ended arterioles and returns to the
vascular system via venous sinuses (29, 30). Due to the pres-
ence of these separate compartments and the property that
lymphocyte entry and exit both occur via the blood, it has
been difficult to study the process of lymphocyte egress from
the spleen. Based on the finding that splenic B and T cell
numbers decrease during the first hours after FTY720 treat-
ment, it has been suggested that the drug does not block
splenic egress and therefore that S1P receptors may not be
involved in this process (11, 17, 18, 31). However, these
studies tracked total spleen cell numbers and did not exclude
the possibility that cells left the nonlymphoid red pulp but
were blocked from exiting the white pulp. Our finding that
S1P1 overexpression decreases B cell localization in the
splenic white pulp and promotes their accumulation in the
red pulp, and that FTY720 treatment can overcome this ef-
fect, provides firm evidence that S1P1 receptor function is
involved in regulating B cell trafficking between the white
and red pulps. This extends the recent finding that trans-
ferred S1P1-deficient lymphocytes accumulate in the splenic
white pulp while being depleted from the red pulp and
blood compared with wild-type cells (6). A unique feature
of the spleen compared with other secondary lymphoid or-
gans is that entry into and exit from the lymphoid area occur
at common locations, the marginal sinus, and marginal zone
bridging regions (2, 32). S1P1-overexpressing B cells were
reduced in number within the splenic white pulp even when
analyzed 4 h after transfer (not depicted). Therefore, we
consider it likely that S1P1 overexpression causes newly ar-
riving cells to immediately take the exit route into the red
pulp. Marginal zone B cells were recently shown to express
higher amounts of S1P1 than follicular cells and their lodg-
ment in the marginal zone was S1P1 dependent (33). As well
as being necessary, our present findings suggest that the high
expression of S1P1 in marginal zone B cells might be suffi-
cient to antagonize their migration into follicles.
In previous studies, it has been found that T cell activa-
tion is associated with a rapid and marked down-regulation
of S1P1 and this has been suggested to provide an explana-
tion for activation-induced T cell retention in lymphoid tis-
sues (6, 22). Our finding that selective restoration of S1P1 by
retroviral gene transduction promotes egress of activated
cells provides evidence that S1P1 down-modulation is suffi-
cient to account for the retention of activated T cells. The
finding that the transduced cells overexpressed S1P1 tran-
scripts by about threefold compared with naive T cells and
left the lymph nodes to a slightly greater extent than naive T
cells in a 15-h assay suggests that endogenous S1P1 expres-
sion levels may limit the rate of naive T cell exit.
In vitro studies with transfected cells have demonstrated
that S1P1 is rapidly down-modulated after exposure to 10–
100 nM S1P (34, 35). Our finding that S1P1 is rapidly down-
modulated on circulating lymphocytes and on isolated lymph
node cells exposed to plasma is in agreement with these find-
ings because blood S1P concentrations are estimated to be
between 100 and 300 nM (7, 36). Measurements of total tis-
sue S1P levels in spleen and other organs indicate concentra-
tions that typically exceed 1pmol S1P per mg wet weight of
tissue (7). However, because all cell types generate S1P intra-
cellularly during normal sphingolipid metabolism and only
some cell types are able to export S1P, much of the total tis-
sue S1P is likely to be intracellular (8). The observation that
S1P1 surface levels recover after lymphocyte migration from
Figure 6. Summary model relating requirements for lymph node 
egress and possible effect of cyclical S1P1 expression on lymphocyte 
recirculation. Lymphocytes in the blood, which has abundant extracellular 
S1P, have little surface S1P1. After migration into a lymphoid organ in an 
integrin- and G i-dependent manner, the cells begin to up-regulate S1P1, 
perhaps because extracellular S1P concentrations are no longer adequate 
to cause receptor down-modulation. Only when S1P1 is up-regulated do the 
cells become fully egress competent and the time required for up-regulation 
may help ensure that the cells dwell in the tissue for a period of hours. Ad-
ditional undefined factors are also anticipated to influence lymphoid organ 
transit time. Egress occurs in a manner that does not require  4 and  2 in-
tegrins but G i contributes to this process, perhaps acting downstream of 
S1P1. Exit sites are suggested to have high S1P levels, and S1P1 signaling is 
essential for egress to occur. By down-modulating S1P1, FTY720 can block 
the egress step. Once in the lymph, S1P1 is down-regulated, most likely due 
to the abundance of S1P, and the cycle begins again. Transit through the 
splenic white pulp is suggested to involve a similar cycle of events except 
that egress is into the blood. The reduced S1P1 levels on circulating lym-
phocytes may also help ensure that S1P does not antagonize chemokine 
signaling required for lymphoid organ entry.JEM VOL. 201, January 17, 2005 299
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blood into spleen and lymph nodes provides evidence that
extracellular S1P concentrations within the lymphoid tissues
are lower than in plasma. Reciprocally, the down-modula-
tion of surface S1P1 on cells within lymph argues that S1P
concentrations are higher in lymph than in lymph nodes.
Taken together, these findings favor the view that egress
from lymphoid tissues is promoted by cells sensing the higher
S1P levels present in lymph (for lymph node and Peyer’s
patch cells) or blood (for spleen cells). Additional factors must
act to ensure that lymphocytes exit lymph nodes and Peyer’s
patches via lymphatics rather than blood vessels.
In summary, we propose that S1P1 down-modulation on
circulating cells helps ensure that after entry into a lymphoid
organ, the cells are not able to immediately undergo the exit
program (Fig. 6). In vitro studies in transfected cells indicate
that after down-modulation, cells require more than 2 h to
fully reexpress the receptor on the cell surface (34, 35) and
our transfer studies suggest that it may take more than an
hour for full S1P1 up-regulation to occur on naive T lym-
phocytes after entry into a lymphoid organ. The finding that
S1P1 heterozygosity is associated with reduced exit efficiency
provides evidence that exit will not be maximal until cells
have fully up-regulated their surface receptor levels. This de-
lay in acquiring full egress competence may help ensure that
newly entering cells are drawn into the parenchyma of the
tissue by lymphoid chemokines rather than undergoing im-
mediate exit, thereby contributing to establishing the half-
day to 1-d residence time of naive lymphocytes within lym-
phoid tissues (37–39). We anticipate that additional factors
such as responsiveness to lymphoid chemokines also contrib-
ute to establishing the transit time. Based on in vitro evi-
dence that S1P can reduce lymphocyte chemokine responses
(40), it can also be suggested that S1P1 down-modulation on
cells within the blood ensures that S1P does not antagonize
lymphoid organ entry.
MATERIALS AND METHODS
Mice and adoptive cell transfer. CD45.2 C57Bl/6 (B6) and CD45.1
B6 mice were from the National Cancer Institutes or a colony maintained
at the University of California, San Francisco, and  2    (41) B6 mice were
from The Jackson Laboratory. IgHEL transgenic B6 mice express IgMa and
IgDa specific for hen egg lysozyme. For adoptive transfers, mice were in-
jected with  1–3   107 cells in  0.3 ml medium. In some experiments,
cells were labeled with CFSE (Molecular Probes) as described previously
(42). Protocols were approved by the Institutional Animal Care and Use
Committee of the University of California, San Francisco.
Antibodies and treatments. The anti- L (clone M17/4, rat IgG2a) hy-
bridoma was from American Type Culture Collection and the anti- 4
(clone PS/2, rat IgG2b) hybridoma was provided by D. Erle (University of
California, San Francisco, San Francisco, CA). Antibodies were adminis-
tered intraperitoneally at 100  g per mouse in PBS. FTY720 (Novartis) was
administered intraperitoneally at 1 mg/kg in saline. Cells were treated with
PBS, 2–200 ng/ml oligomer B, or PTX (Sigma-Aldrich) for the indicated
times at 37 C as described previously (30), washed twice in warm RPMI
1640, 2% FCS, and 10 mM Hepes, and then assayed or transferred to recip-
ient mice. S1P1-specific antiserum was generated by immunizing rabbits ac-
cording to standard procedures (AnimalPharm Services) with a glutathione-
S-transferase fusion protein containing the first 49 amino acids of mouse
S1P1. The antiserum was affinity purified using sepharose beads coupled to a
mannose binding protein fusion containing the same segment of S1P1. An
affinity-purified antiserum raised against the cytoplasmic domain of mouse
BAFF was used as a control.
Epitope-tagged S1P1. Full-length murine S1P1  was inserted into the
MSCV2.2 retroviral vector in frame with a preprolactin leader sequence and
Flag epitope and upstream of an internal ribosomal entry site and a cytoplas-
mic domain truncated hCD4 (42). In the vector control, a second copy of the
truncated hCD4 was inserted in place of the preprolactin leader, Flag epitope
and S1P1. Retrovirus-containing culture supernatant was generated using the
Bosc23-packaging cell line and primary B cell retroviral infection was with Ig-
HEL transgenic B cells as described previously (42). Primary T cell retroviral in-
fection was performed by incubating total splenocytes at  107 per ml for 20–
24 h on 24-well plates precoated for 2–3 h at 37 C with 3  g/ml anti-CD3
and 0.5  g/ml anti-CD28 (BD Biosciences). Activated T cells were spin in-
fected at 2,450 RPM in a Beckman Coulter Allegra 6R centrifuge for 2 h at
25 C as described previously (42), and then cultured in vitro for 24 h before
transfer to recipient mice or incubated in vitro for 48 h. In vitro–incubated
transduced T cells were purified by autoMACS (Miltenyi Biotec) by deplet-
ing CD11b , Mac-1 , B220 , I-Ab , and Gr-1  cells, and RNA was isolated
using QIAGEN RNeasy kits treated with DNaseI, and real-time quantitative
PCR was performed for total S1P1 mRNA relative to HPRT by using SYBR
Green (Applied Biosystems). The primers used for quantitative PCR were
S1P1 forward CCTTCATCCGGATCGTATCT, S1P1 reverse TGCTGCG-
GCTAAATTCCATG, HPRT forward AGGTTGCAAGCTTGCTGGT,
and HPRT reverse TGAAGTACTCATTATAGTCAAGGGCA.
Immunohistochemical and flow cytometric analysis. 7- m cryostat
sections were fixed and stained as described previously (42) using the fol-
lowing antibodies: B220, MAdCAM-1, and hCD4-biotin (BD Bio-
sciences). Amplification of the hCD4 signal was performed by using the
Tyramide Signal Amplification Biotin System (NEN Life Science Products)
by first quenching endogenous peroxidase activity by incubating sections in
0.045% H2O2 for 15 min at room temperature and then adhering to the
manufacturer’s protocol. Enumeration of transferred cells in white pulp
cords were performed as described previously (2). Flow cytometric analysis
was performed on a FACSCalibur (Becton Dickinson). Transferred trans-
duced B cells were identified flow cytometrically by staining for CD45.1,
B220, and hCD4. Transferred transduced T cells were identified by staining
for CD45.1, CD4 and CD8, and hCD4. CD4 and CD8 antibodies were
typically combined in the same channel and were distinguished by the more
intense fluorescence of the CD8 cells. All monoclonal antibodies used were
from BD Biosciences. Flag levels were detected by staining with the M2-
Flag antibody (Sigma-Aldrich). CFSE-labeled cells were detected by stain-
ing for B220, CD4, or CD8. Integrin saturation with anti- L and anti- 4
antibodies was determined as described previously (2). For detecting endog-
enous S1P1, cells were incubated with affinity purified rabbit anti-S1P1
( 20  g/ml) for 1.5 h followed by anti–rabbit IgG biotin (BD Biosciences)
and lastly with CD45.2-PE, L-selectin–FITC, CD4-PerCP (BD Bio-
sciences), and streptavidin-APC (Molecular Probes). Thymocyte popula-
tions were distinguished by CD4, CD8, and L-selectin staining. Blood lym-
phocytes were prepared by lysing red blood cells twice on ice with a tris
ammonium chloride solution. Mouse plasma was prepared by diluting nine
parts whole blood into one part acid-citrate-dextrose solution (Sigma-
Aldrich), spinning at 83 g for 10 min, removing the clear, top fraction, and
spinning at 630 g for 10 min and retaining the supernatant.
Chemotaxis assays. Cells were tested for transmigration across uncoated
5- m transwell filters (Corning Costar Corp.) for 3 h to S1P (Sigma-Aldrich),
CXCL12 (SDF-1; PeproTech), or CCL21 (SLC; R&D Systems), or medium
in the bottom chamber and were enumerated by flow cytometry (43).
Online supplemental material. Fig. S1 shows flow cytometric analysis of
S1P1 expression on thymocytes from 8-wk reconstituted S1P1
    or S1P1
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tal liver chimeras that had been generated as described previously (6), from sa-
line- or FTY720-treated wild-type mice and from S1P1
 /  mice. Fig. S1 is
available at http://www.jem.org/cgi/content/full/jem.20041509/DC1.
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